Older adults are being advised to limit the number of anticholinergic medicines they take and to use the lowest effective dose for the shortest time needed, according to guidance highlighted by the Medicines and Healthcare products Regulatory Agency (MHRA). The advice focuses on reducing unnecessary exposure in older patients, who may be more vulnerable to medicine-related side effects.
The warning follows a review of 17 studies looking at a possible connection between anticholinergic medicines and dementia. However, the evidence was judged to be at serious or critical risk of bias, meaning the review could neither confirm nor rule out a causal link. In practical terms, regulators are urging caution rather than saying these medicines definitely cause dementia.
The message for clinicians and patients is to weigh benefits and risks carefully, especially when several anticholinergic medicines are being used at the same time. Where treatment is needed, the current advice is to keep use to the minimum required to manage symptoms effectively.
The update underscores a broader medication safety issue for older adults: regular review of prescriptions can help avoid unnecessary drug burden. While the dementia question remains unresolved, the MHRA’s position is that limiting anticholinergic use where possible is a sensible step until stronger evidence is available.
